CLIA-certified drug response testing for high-grade glioma, run on the patient's own fresh tumor tissue.
Consented intake · your records travel with you · nothing moves without your sign-off
Kiyatec provides CLIA-certified functional testing for high-grade glioma brain cancer. Drugs are applied to fresh tumor tissue and the response is observed, with results in two days to six weeks. For glioma patients deciding on treatment, ex vivo response data can add confidence that a drug or combination is likely to work before it is administered.
Prefer the source? Kiyatec (CLIA-certified, high-grade glioma brain cancer)'s own site has more.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Kiyatec (CLIA-certified, high-grade glioma brain cancer) handles billing.
We don't have confirmed insurance details for Kiyatec (CLIA-certified, high-grade glioma brain cancer) yet. Start a coverage check with your plan, or contact the provider directly.
Answers grounded in Kiyatec's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Other providers in similar categories.
Gather distinctive biomarkers that can guide treatment and monitor disease progression
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Finds clinical trials you actually qualify for — matched to your tumor's biomarkers and treatment history, not a generic keyword search.
This page is general information. Upload your records for analysis specific to YOUR diagnosis.